{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:22:05Z","timestamp":1792297325645,"version":"4.4.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Ruxolitinib is a potent Janus kinase (JAK) 1\/JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large (\n                    <jats:italic>N<\/jats:italic>\n                    \u00a0=\u00a02233), phase 3b, expanded\u2010access study in MF in countries without access to ruxolitinib outside a clinical trial, which included patients with low platelet counts (&lt;100\u00a0\u00d7\u00a010\n                    <jats:sup>9<\/jats:sup>\n                    \/l) and patients without splenomegaly \u2013 populations that have not been extensively studied. The most common adverse events (AEs) were anaemia and thrombocytopenia, but they rarely led to discontinuation (overall, 5\u00b74%; low\u2010platelet cohort, 12\u00b73%). As expected, rates of worsening thrombocytopenia were higher in the low\u2010platelet cohort (all grades, 73\u00b72% vs. 53\u00b75% overall); rates of anaemia were similar (all grades, 52\u00b79% vs. 59\u00b75%). Non\u2010haematologic AEs, including infections, were mainly grade 1\/2. Overall, ruxolitinib led to meaningful reductions in spleen length and symptoms, including in patients with low platelet counts, and symptom improvements in patients without splenomegaly. In this trial, the largest study of ruxolitinib in patients with MF to date, the safety profile was consistent with previous reports, with no new safety concerns identified. This study confirms findings from the COMFORT studies and supports the use of ruxolitinib in patients with platelet counts of 50\u2013100\u00a0\u00d7\u00a010\n                    <jats:sup>9<\/jats:sup>\n                    \/l. (ClinicalTrials.gov identifier NCT01493414).\n                  <\/jats:p>","DOI":"10.1111\/bjh.16462","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T06:05:49Z","timestamp":1580796349000},"page":"888-903","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Primary analysis of JUMP, a phase 3b, expanded\u2010access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts"],"prefix":"10.1111","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-2239","authenticated-orcid":false,"given":"Haifa Kathrin","family":"Al\u2010Ali","sequence":"first","affiliation":[{"name":"Universit\u00e4tsklinikum Halle Halle (Saale) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-7004","authenticated-orcid":false,"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[{"name":"Johannes Wesling Medical Center Minden University Clinic for Hematology, Oncology, Hemostaseology, and Palliative Care UKRUB University of Bochum Minden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Foltz","sequence":"additional","affiliation":[{"name":"St Paul\u2019s Hospital University of British Columbia Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate \u201cG.F. Ingrassia\u201d University of Catania Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera \u201cBianchi Melacrino Morelli\u201d Reggio Calabria Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology \u201cSer\u00e0gnoli\u201d Institute of Hematology University of Bologna School of Medicine Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[{"name":"University of Perugia Azienda Ospedaliera S. Maria Terni Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garc\u00eda\u2010Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Hospital General de Alicante Alicante Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Zaritskey","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre St Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Tavares","sequence":"additional","affiliation":[{"name":"Universidade Federal de Goi\u00e1s Goi\u00e1s Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Davidoff Cancer Center Rabin Medical Center Petah Tikva, and Sackler School of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Miguel Servet University Hospital and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER) Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[{"name":"Klinikum Chemnitz gGmbH Chemnitz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-4468","authenticated-orcid":false,"given":"Daniela","family":"Damiani","sequence":"additional","affiliation":[{"name":"University of Udine Udine Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-6595","authenticated-orcid":false,"given":"Tomasz","family":"Sacha","sequence":"additional","affiliation":[{"name":"Jagiellonian University Krak\u00f3w Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bouard","sequence":"additional","affiliation":[{"name":"Novartis Pharma S.A.S. Rueil\u2010Malmaison France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Paley","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt Ltd Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mannelli","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliero\u2010Universitaria Careggi University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliero\u2010Universitaria Careggi University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.2376.2376"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00529-8"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527903"},{"key":"e_1_2_9_10_1","unstructured":"Gupta V. Griesshammer M. Martino B. Foltz L. Tavares R. Al\u2010Ali H.K. Giraldo P. Guglielmelli P. Lomaia E. Bouard C. Perez Ronco J. Tiwari R.&Raanani P.(2017)Predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded\u2010access JUMP study PF616."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3082-y"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1179545X17695233"},{"key":"e_1_2_9_15_1","unstructured":"Jakafi (ruxolitinib)(2017)package insert.Incyte Corporation Wilmington Delaware USA."},{"key":"e_1_2_9_16_1","unstructured":"Jakavi (ruxolitinib)(2016)[summary of product characteristics].Novartis Pharmaceuticals UK Limited Horsham West Sussex UK."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0027-y"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2208-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18674"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_2_9_21_1","first-page":"E1333","article-title":"Comparing the safety and efficacy of ruxolitinib (RUX) in patients (PTS) with DIPSS low\/intermediate\u20101\u2013, intermediate\u20102\u2013, and high\u2010risk myelofibrosis (MF) in JUMP, a phase 3B, expanded\u2010access study","volume":"102","author":"Passamonti F.","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695957"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-81"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23703"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24592"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119545"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.204602"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S53348"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0527-7"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16462","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T13:03:37Z","timestamp":1693573417000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/bjh.16462"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16462","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"2019-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}